Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership

Sep 02 2017

• By Mandy Jackson

Halozyme CEO Helen Torley — Halozyme President and CEO Helen Torley • Source: Halozyme Therapeutics Inc.

Related Content

FDA's NDA And BLA Approvals: Cotempla XR-ODT, Baxdela, Mydayis, Rituxan Hycela, Haegarda

Jun 23 2017

Imperfect Dataset Bolsters Halozyme's Biomarker Plan For PEGPH20

Jan 06 2017

Phase Ib pancreatic cancer data demonstrate Halozyme hyaluronan thesis

Oct 01 2013

Deal Watch: Merck’s Next Move In Cancer Immunotherapy Is BET Inhibitor, Bispecifics Gaining Steam

Dec 22 2014

Roche Invests In Halozyme Biologics Delivery Platform

Dec 06 2006

Baxter, Halozyme win FDA OK for HyQvia

Sep 16 2014

J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches

Oct 19 2016

AbbVie collaboration boosts Halozyme stock

Jun 04 2015

Halozyme Lands Latest Partner In Lilly

Dec 22 2015

Halozyme’s “Hat Collector” Approach To Human Capital: Virtue in Versatility

Aug 28 2017

Pfizer’s Bococizumab Discontinuation Increases Uncertainty For Other PCSK9s

Nov 02 2016

Finance Watch: Two More US Biopharma IPOs And Two New European VC Funds

May 20 2017

Halozyme rockets 30% on potential $515M deal with Pfizer

Dec 22 2012

Related Companies

Halozyme Therapeutics, Inc.

Roche Holding AG

Bristol Myers Squibb Company

Merck & Co., Inc.

Eisai Co., Ltd.

Takeda Pharmaceutical Co. Ltd.

Baxalta Incorporated

Pfizer Inc.

Johnson & Johnson

AbbVie Inc.

Eli Lilly and Company

Additional Topics

Business Strategies Deals Companies Commercial Cancer BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window